Kenneth Mills Biography and Net Worth

CEO of REGENXBIO


Kenneth T. Mills has been our President, Chief Executive Officer and Director since March 2009. Mr. Mills was with FOXKISER LLP (“FOXKISER”), most recently as a Partner, from January 2007 to January 2015. Mr. Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a life sciences company, from January 2004 to December 2006 and was part of the original management team that established the company’s operations and financing strategy. From March 1997 to December 2003, Mr. Mills was employed at IGEN, a biotechnology company, where he served as Director of Business Development up through the company’s acquisition by Roche. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology. Mr. Mills’ qualifications to continue to serve as a member of the Board include his extensive experience as an executive in the gene therapy and biotechnology industries, including as President and Chief Executive Officer of our Company, his prior service as a senior-level executive in both early stage and mature biotechnology companies and his demonstrated business judgment. Provided by Tagnifi.

What is Kenneth T. Mills' net worth?

The estimated net worth of Kenneth T. Mills is at least $6.63 million as of April 15th, 2024. Mr. Mills owns 408,035 shares of REGENXBIO stock worth more than $6,634,649 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Mills may own. Additionally, Mr. Mills receives a salary of $1,020,000.00 as CEO at REGENXBIO. Learn More about Kenneth T. Mills' net worth.

How old is Kenneth T. Mills?

Mr. Mills is currently 49 years old. There are 7 older executives and no younger executives at REGENXBIO. The oldest executive at REGENXBIO is Dr. Laura A. Coruzzi J.D., Ph.D., Executive Vice President of Intellectual Property, who is 70 years old. Learn More on Kenneth T. Mills' age.

What is Kenneth T. Mills' salary?

As the CEO of REGENXBIO Inc., Mr. Mills earns $1,020,000.00 per year. The highest earning executive at REGENXBIO is Mr. Patrick J. Christmas II, J.D., Executive VP & Chief Legal Officer, who commands a salary of $1,110,000.00 per year. Learn More on Kenneth T. Mills' salary.

How do I contact Kenneth T. Mills?

The corporate mailing address for Mr. Mills and other REGENXBIO executives is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. REGENXBIO can also be reached via phone at (240) 552-8181 and via email at [email protected]. Learn More on Kenneth T. Mills' contact information.

Has Kenneth T. Mills been buying or selling shares of REGENXBIO?

During the last quarter, Kenneth T. Mills has sold $272,850.00 of REGENXBIO stock. Most recently, Kenneth T. Mills sold 15,000 shares of the business's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.19, for a transaction totalling $272,850.00. Following the completion of the sale, the chief executive officer now directly owns 408,035 shares of the company's stock, valued at $7,422,156.65. Learn More on Kenneth T. Mills' trading history.

Who are REGENXBIO's active insiders?

REGENXBIO's insider roster includes Allan Fox (Director), Kenneth Mills (CEO), Kenneth Mills (CEO), and Steve Pakola (Insider). Learn More on REGENXBIO's active insiders.

Are insiders buying or selling shares of REGENXBIO?

In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 165,115 shares worth more than $3,085,821.51. The most recent insider tranaction occured on April, 15th when CEO Kenneth T Mills sold 15,000 shares worth more than $272,850.00. Insiders at REGENXBIO own 13.1% of the company. Learn More about insider trades at REGENXBIO.

Information on this page was last updated on 4/15/2024.

Kenneth T. Mills Insider Trading History at REGENXBIO

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/15/2024Sell15,000$18.19$272,850.00408,035View SEC Filing Icon  
3/14/2024Sell15,000$21.86$327,900.00408,035View SEC Filing Icon  
2/14/2024Sell15,000$16.76$251,400.00408,035View SEC Filing Icon  
1/16/2024Sell45,000$15.18$683,100.00408,035View SEC Filing Icon  
12/19/2023Sell45,000$19.68$885,600.00355,289View SEC Filing Icon  
11/8/2021Sell1,500$40.00$60,000.00View SEC Filing Icon  
9/27/2021Sell1,500$42.19$63,285.00View SEC Filing Icon  
6/24/2021Sell4,500$40.02$180,090.00285,484View SEC Filing Icon  
1/25/2021Sell6,500$44.74$290,810.00287,484View SEC Filing Icon  
1/7/2021Sell1,500$50.01$75,015.00283,484View SEC Filing Icon  
12/23/2020Sell4,500$50.00$225,000.00245,500View SEC Filing Icon  
12/16/2020Sell15,000$45.00$675,000.00256,000View SEC Filing Icon  
12/10/2020Sell4,500$40.00$180,000.00245,500View SEC Filing Icon  
9/19/2019Sell10,000$39.75$397,500.00251,000View SEC Filing Icon  
8/19/2019Sell15,000$37.55$563,250.00261,000View SEC Filing Icon  
7/19/2019Sell15,000$49.49$742,350.00261,000View SEC Filing Icon  
6/19/2019Sell15,000$52.54$788,100.00261,000View SEC Filing Icon  
5/20/2019Sell15,000$42.99$644,850.00261,000View SEC Filing Icon  
4/22/2019Sell15,000$50.44$756,600.00261,000View SEC Filing Icon  
3/19/2019Sell15,000$58.53$877,950.00261,000View SEC Filing Icon  
2/15/2019Sell15,000$47.29$709,350.00261,000View SEC Filing Icon  
1/15/2019Sell15,000$43.85$657,750.00204,140View SEC Filing Icon  
12/17/2018Sell15,000$46.73$700,950.00223,396View SEC Filing Icon  
11/26/2018Sell20,000$64.17$1,283,400.00259,620View SEC Filing Icon  
11/21/2018Sell15,000$61.44$921,600.00284,700View SEC Filing Icon  
11/12/2018Sell20,000$63.11$1,262,200.00View SEC Filing Icon  
11/5/2018Sell20,000$68.25$1,365,000.00322,500View SEC Filing Icon  
10/15/2018Sell7,510$59.35$445,718.50331,710View SEC Filing Icon  
9/17/2018Sell7,510$74.91$562,574.10339,505View SEC Filing Icon  
8/27/2018Sell7,510$66.46$499,114.60348,530View SEC Filing Icon  
6/20/2018Sell5,000$66.20$331,000.00208,330View SEC Filing Icon  
5/21/2018Sell10,000$47.05$470,500.00View SEC Filing Icon  
4/20/2018Sell10,000$39.52$395,200.00219,430View SEC Filing Icon  
3/20/2018Sell10,000$29.55$295,500.00228,530View SEC Filing Icon  
2/20/2018Sell10,000$26.56$265,600.00238,530View SEC Filing Icon  
1/22/2018Sell10,000$27.33$273,300.00248,530View SEC Filing Icon  
12/20/2017Sell10,000$31.75$317,500.00108,530View SEC Filing Icon  
11/20/2017Sell10,000$27.71$277,100.00View SEC Filing Icon  
10/20/2017Sell10,000$32.62$326,200.0098,730View SEC Filing Icon  
9/20/2017Sell10,000$29.33$293,300.00108,630View SEC Filing Icon  
9/5/2017Sell10,500$25.00$262,500.00118,530View SEC Filing Icon  
8/21/2017Sell6,500$20.05$130,325.00105,500View SEC Filing Icon  
7/20/2017Sell6,500$18.66$121,290.00112,000View SEC Filing Icon  
6/20/2017Sell6,500$19.68$127,920.00119,396View SEC Filing Icon  
4/24/2017Sell15,440$20.98$323,931.20126,395View SEC Filing Icon  
See Full Table

Kenneth T. Mills Buying and Selling Activity at REGENXBIO

This chart shows Kenneth T Mills's buying and selling at REGENXBIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

REGENXBIO Company Overview

REGENXBIO logo
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $16.19
Low: $15.72
High: $16.45

50 Day Range

MA: $19.92
Low: $15.64
High: $24.61

2 Week Range

Now: $16.19
Low: $11.83
High: $28.80

Volume

305,658 shs

Average Volume

714,704 shs

Market Capitalization

$793.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29